CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 184,135	$ 143,663
Accounts receivable	50,507	488
Prepaid expenses	12,632	17,434
Other current assets	418	169
Total current assets	247,692	161,754
Property, equipment, and software—net	23,053	25,154
Intangible assets—net	1,995	2,048
Right-of-use assets—net	3,595	4,180
Investment in equity securities	3,091	3,091
Equity method investment	1,351	3,751
Note receivable—net	7,054	6,879
Other assets	9,332	4,641
Total assets	297,163	211,498
Current liabilities:
Accounts payable	797	1,144
Accrued compensation	4,050	6,765
Accrued clinical and research and development expenses	4,186	4,028
Deferred revenue	41,514	21,244
Lease liabilities	1,927	1,822
Other current liabilities	1,449	977
Total current liabilities	53,923	35,980
Deferred revenue	104,048	67,015
Lease liabilities	3,823	4,813
Long term debt—net	22,119	2,478
Contract liabilities	10,000	10,000
Other noncurrent liabilities	227	44
Total liabilities	194,140	120,330
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value— 10,000,000 shares authorized as of June 30, 2022 and December 31, 2021; no shares issued and outstanding as of June 30, 2022 and December 31, 2021
Common stock; $0.000005 par value— 200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 111,605,505 shares issued and 110,795,033 shares outstanding as of June 30, 2022; 61,712,577 shares issued and 60,902,105 shares outstanding as of December 31, 2021
Additional paid-in capital	479,853	408,795
Accumulated deficit	(375,878)	(316,675)
Treasury stock	(952)	(952)
Total stockholders’ equity	103,023	91,168
Total liabilities and stockholders’ equity	$ 297,163	$ 211,498